Recursion Pharmaceuticals, Inc. (BMV:RXRX)
Mexico
· Delayed Price · Currency is MXN 62.00
0.00 (0.00%)
At close: Mar 6, 2026
Recursion Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Net Income | -644.76 | -463.66 | -328.07 | -239.48 | -186.48 | Upgrade
|
| Depreciation & Amortization | 83.7 | 36.49 | 24.4 | 11.76 | 8.41 | Upgrade
|
| Loss (Gain) From Sale of Assets | 4.5 | - | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 28.04 | 0.11 | 1.19 | 2.81 | - | Upgrade
|
| Stock-Based Compensation | 111.22 | 81.69 | 53.5 | 27.91 | 14.84 | Upgrade
|
| Other Operating Activities | 31.8 | 32.96 | 5.45 | 8.56 | 4.92 | Upgrade
|
| Change in Accounts Receivable | 32.94 | -6.07 | -7.76 | -0 | -5.38 | Upgrade
|
| Change in Accounts Payable | -2.62 | 6.44 | -0.99 | 1.77 | 1.75 | Upgrade
|
| Change in Unearned Revenue | -36.77 | -28.04 | -41.08 | 110.32 | -10 | Upgrade
|
| Change in Other Net Operating Assets | 20.14 | -19.08 | 5.56 | -7.16 | 13.33 | Upgrade
|
| Operating Cash Flow | -371.81 | -359.17 | -287.78 | -83.52 | -158.61 | Upgrade
|
| Capital Expenditures | -6.47 | -13.7 | -11.96 | -37.06 | -39.8 | Upgrade
|
| Cash Acquisitions | - | 277.1 | 1.84 | - | - | Upgrade
|
| Divestitures | -4.44 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -2.16 | -3.35 | -0.6 | -0.3 | - | Upgrade
|
| Investment in Securities | -3.81 | - | 0.48 | 230.61 | -231.95 | Upgrade
|
| Investing Cash Flow | -16.87 | 260.06 | -10.23 | 193.25 | -271.74 | Upgrade
|
| Long-Term Debt Repaid | -8.43 | -4.44 | -0.77 | -0.09 | -12.8 | Upgrade
|
| Net Debt Issued (Repaid) | -8.43 | -4.44 | -0.77 | -0.09 | -12.8 | Upgrade
|
| Issuance of Common Stock | 532.96 | 308.56 | 140.9 | 154.44 | 471.34 | Upgrade
|
| Other Financing Activities | -3 | - | - | - | - | Upgrade
|
| Financing Cash Flow | 521.53 | 304.12 | 140.13 | 154.35 | 458.54 | Upgrade
|
| Foreign Exchange Rate Adjustments | 18.04 | -3.41 | 0.19 | -0.31 | - | Upgrade
|
| Net Cash Flow | 150.9 | 201.6 | -157.69 | 263.76 | 28.18 | Upgrade
|
| Free Cash Flow | -378.28 | -372.87 | -299.74 | -120.58 | -198.41 | Upgrade
|
| Free Cash Flow Margin | -506.52% | -633.71% | -672.43% | -302.64% | -1949.42% | Upgrade
|
| Free Cash Flow Per Share | -0.84 | -1.36 | -1.44 | -0.69 | -1.58 | Upgrade
|
| Cash Interest Paid | - | - | - | - | 0.68 | Upgrade
|
| Levered Free Cash Flow | -208.52 | -194.33 | -187.37 | -105.41 | -121.93 | Upgrade
|
| Unlevered Free Cash Flow | -207.39 | -193.35 | -187.31 | -105.37 | -120.09 | Upgrade
|
| Change in Working Capital | 13.69 | -46.76 | -44.26 | 104.92 | -0.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.